Diastolic Robotics' mission is to improve patient care.
To these ends Diastolic Robotics Incorporated (DRI) works in medicine and engineering, developing drug and device solutions.
Diastolic Robotics™ — also known as diarobo™ —
was started to commercialize products in the surgical robotics space, specifically
surgical tools for heart stabilization during coronary artery bypass procedures.
One such device was THASA, the Tissue and Heart Stabilization Tool, which is described
in United States patent:
6,210,323 Surgical arm and tissue stabilizer
. THASA held sections of the heart still for coronary artery bypass grafting procedures, allowing work to progress off-pump.
Following that, DRI expanded into medical device consulting and software development. Some of the software projects include simulation and modelling programs:
Currently DRI's software projects include apps and other software for medical professionals. These projects include:
More recently, DRI is commercializing products for individualizing drug therapies, specifically neuromuscular blockers (NMB), but with many other indications in mind. NMB drugs are safe, but subject to frequent incidences of under- and overdosing due to dose by weight regimens. We have a solution that reduces (as shown in 60 patient clinical trial, please follow the following link to see the references) these incidences. Please view the NMB Projects page for more details.
Great news to come.
diarobo and "Diastolic Robotics" are trademarks of Diastolic Robotics Incorporated
© 2012 Diastolic Robotics Incorporated